Core Viewpoint - The lawsuit against BellRing Brands, Inc. alleges that the company and its executives misled investors regarding the true drivers of its sales growth, which was primarily due to retailers hoarding inventory rather than genuine consumer demand [3][5]. Company Overview - BellRing Brands, Inc. is facing a securities fraud lawsuit that claims misleading statements were made about the sustainability and drivers of its sales growth, as well as the competitive landscape affecting demand for its products [5][6]. Allegations of Misleading Information - The lawsuit contends that BellRing's reported sales growth in 2025 was artificially inflated due to retailers stockpiling inventory to prevent shortages, which was not reflective of actual consumer demand [3][7]. - A significant drop in BellRing's share price occurred after disclosures revealed that retailers were reducing their inventory levels, leading to a 33% decline in share price on August 4, 2025 [3][7]. Financial Impact - Following disappointing financial results for Q2 2025, BellRing's CFO admitted that some retailers had been hoarding inventory, which contributed to a 19% drop in share price [7]. - The Q3 2025 financial results further revealed a narrowed sales outlook, resulting in a severe market reaction with a 33% drop in share price, attributed to increased competition and lower consumption rates [7]. Legal Proceedings - The lead plaintiff deadline for the lawsuit is set for March 23, 2026, and investors who suffered losses during the specified period are encouraged to participate [1][6].

Core Viewpoint - A class action lawsuit has been filed against Picard Medical, Inc. for alleged securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves allegations that Picard and certain officers and/or directors engaged in securities fraud [2]. - Investors have until April 3, 2026, to request to be appointed as Lead Plaintiff if they purchased Picard securities during the Class Period [2]. Group 2: Stock Price Surge - Picard's stock price increased from its IPO price of $4.00 per share to an all-time high of $13.68 per share before October 23, 2025, without any fundamental news to justify this rise [4]. - Investigations revealed that the stock price was artificially inflated through an illicit social-media promotion scheme, where impersonators made sensational claims to incite buying among retail investors [4]. Group 3: Law Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [5]. - The firm has a track record of recovering multimillion-dollar damages for class members [5].

Core Viewpoint - A class action lawsuit has been filed against Masonite International Corporation, alleging securities fraud and unlawful business practices related to stock repurchases during a specific period [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Masonite and its officers/directors engaged in securities fraud by failing to disclose multiple formal acquisition offers from Owens Corning while repurchasing its own stock at lower market prices [4]. - Investors who sold Masonite common stock during the Class Period have until April 7, 2026, to request to be appointed as Lead Plaintiff [2]. Group 2: Company Background - Pomerantz LLP, the firm handling the lawsuit, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [5].

Core Viewpoint - ICON Public Limited Company is under investigation for potential violations of federal securities laws, following a significant decline in shareholder value due to a revenue overstatement and a delay in financial results release [1][2]. Financial Performance and Market Reaction - The company's stock experienced a substantial single-day decline, erasing billions in shareholder value and marking one of the largest percentage drops in the Contract Research Organization (CRO) sector in recent years [2]. - Prior to the disclosure, ICON's stock was trading within a range that indicated investor confidence, with a full-year 2025 revenue guidance of $8.05 billion to $8.1 billion and adjusted EPS guidance of $13.00 to $13.20, figures affirmed by management as of October 23, 2025 [2][3]. Revenue Overstatement and Guidance Delay - ICON disclosed a preliminary revenue overstatement of under two percent per year for fiscal years 2023 and 2024, which led to the delay of its Q4 and full-year 2025 results [3]. - The CEO had previously assured investors that the company's performance was "broadly in line with expectations," while the CFO reported Q3 2025 revenue of $2.043 billion, reflecting a year-over-year increase of 0.6 percent [3]. Stock Buyback Activity - In the quarters leading up to the disclosure, ICON repurchased $750 million of its own stock and had a new $1 billion buyback authorization approved by its board, indicating prior confidence in its financial position [4]. - A filing on January 7, 2026, indicated that full-year 2026 guidance would be released alongside the delayed Q4 and full-year 2025 results, a timeline now affected by the announcement of the delay [4].

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Kyndryl and certain of it ...

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices by the company and certain officers and/or directors [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by April 6, 2026 [2]. - A copy of the Complaint related to the class action can be accessed at Pomerantz's website [2]. Group 2: Company Performance and Stock Impact - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical Inc. announced that the Phase 3 Orbit study was progressing towards a final analysis, leading to a significant drop in Mereo's ADR price by $1.25, or 42.52%, closing at $1.69 on July 10, 2025 [4]. - On December 29, 2025, Mereo reported that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, resulting in a drastic decline in ADR price by $2.02, or 87.7%, closing at $0.29 [5].

Core Viewpoint - Medpace Holdings, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price despite reporting strong Q4 earnings [1][2]. Financial Performance - Medpace reported Q4 revenue of $708.5 million and GAAP EPS of $4.67, both exceeding Wall Street consensus estimates [2]. - The company's shares fell approximately 10% by mid-day and closed down 15.9%, with a trading volume of about $10.2 million during the sell-off, indicating heightened trading activity [2]. Market Reaction - The decline in stock price was attributed to a bookings shortfall, which overshadowed the positive sales and profit figures [3]. - The book-to-bill ratio missed expectations, leading to a sharp decline in stock price and raising concerns about future demand [3]. Institutional Activity - Principal Financial Group reduced its stake in Medpace by 8.4% prior to the earnings release, while Representative David Taylor purchased shares shortly before [4]. - The timing of these transactions is relevant to the ongoing investigation [4]. Analyst Commentary - Analysts questioned management about the nature of booking deterioration during the Q4 earnings call, highlighting concerns over direct-fee growth and cancellation levels [5]. - Management acknowledged that the level of cancellations was the highest compared to the previous year, describing them as "broad-based" without providing clear reasons [5].

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Richtech Robotics Inc. (“Richtech” or the “Company”) (NASDAQ: RR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Richtech and certain o ...

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for alleged securities fraud and unlawful business practices following the failure of a key clinical trial [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Vistagen and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until March 16, 2026, to request to be appointed as Lead Plaintiff if they purchased Vistagen securities during the Class Period [2]. Group 2: Clinical Trial Outcome - On December 17, 2025, Vistagen announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for treating social anxiety disorder did not show statistically significant improvement on the primary endpoint [4]. - The trial results indicated no treatment difference between fasedienol and placebo for the secondary endpoint [4]. Group 3: Stock Price Impact - Following the announcement of the trial results, Vistagen's stock price fell by $3.499 per share, representing an 80.25% decline, closing at $0.861 per share on December 17, 2025 [5].

Core Viewpoint - Hagens Berman is notifying investors about a securities class action against Klarna Group plc, focusing on alleged misstatements in the company's September 2025 IPO documents [1][4]. Group 1: Allegations and Investigation - The investigation centers on claims that Klarna's IPO documents misled investors by highlighting its credit modeling performance while failing to disclose aggressive lending practices to financially unsophisticated consumers [4][8]. - The complaint alleges that Klarna's offering documents materially understated the credit risks associated with lending to clients experiencing financial hardship [8]. - Following the IPO, Klarna reported a 102% year-over-year increase in its provision for credit losses, raising concerns about the transparency of its IPO documents [4][5][8]. Group 2: Financial Impact - Just weeks after the IPO, Klarna's stock price fell nearly 22% below the $40 IPO price due to the revelation of increased credit loss provisions [4][8]. - The significant spike in credit loss provisions indicates potential flaws in Klarna's credit modeling, which was previously presented as robust [8]. Group 3: Next Steps for Investors - Investors who purchased Klarna shares during the September 2025 IPO and incurred losses are encouraged to contact Hagens Berman for assistance [3][6]. - The lead plaintiff deadline for the class action is set for February 20, 2026 [1][7].